Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
dabrafenib
BRF113929
NCT01266967
Melanoma
Phase 2
 
June 2017

Powered by ideaPoint, Inc.